Stock Quote

Repros Therapeutics Inc. (RPRX.W) (NASD ADF)
As of  9:55am EST
0.72USD
Price Change
+0.00
Percent Change
+0.00%
 
$0.72
9:55am EST
+0.00%
$0.72
$0.72
500
$0.72
$0.72
$13.94
$0.65
-0.02
781,219

Research Another Stock: Symbol Look-up
Genzyme's Termeer: Worst Biotech CEO of '09
Tuesday, 17 Nov 2009 12:31pm EST(The Street) 
Collagen Disease Breakthrough
Monday, 16 Nov 2009 09:00am EST(The Street) 
A Three-Way Strategy on Repros Therapeutics
Monday, 26 Oct 2009 08:40am EDT(Seeking Alpha) 
Early Movers: Pump Up the Volume
Wednesday, 7 Oct 2009 08:51am EDT(The Street) 
Oculus Insider to Sell Diluted Bleach Water: BioBuzz
Tuesday, 29 Sep 2009 01:35pm EDT(The Street) 
 
Name Current Position Compensation
Masterson, Nola Chairman of the Board --
Podolski, Joseph President, Chief Executive Officer, Director 703,539
Van As, Andre Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs 399,667

Profile

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of... Full Description

Company Address

Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands   TX   77380
P: +1281.7193400
F: +1281.7193446

Analyst Research

Performance of Key Competitors

Company Price Change
Schering-Plough Corporation -- --
Solvay S.A. €71.92 +1.25
Auxilium Pharmaceuticals, Inc. $35.04 +0.11
  RPRX.W Industry
P/E(TTM) -- 12.80
P/S(TTM) 188.65 29.90
ROI(TTM) -452.83 2.35
ROE(TTM) -452.83 3.59
Consensus Recommendation Underperform
EPS Est. (Current Period) -0.35
EPS Est. (Current Year) -2.10
Total Revenue $0.00M
Net Income $-8.89M
EPS $-0.59